NASDAQ:HRTS Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) Price, Holdings, & News $27.98 -0.29 (-1.03%) As of 06/20/2025 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$27.98▼$28.3750-Day Range$26.75▼$29.2052-Week Range$25.32▼$36.03Volume3,247 shsAverage Volume9,815 shsMarket Capitalization$53.16 millionAssets Under Management$50.25 millionDividend Yield1.64%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.Read More… Tema GLP-1, Obesity & Cardiometabolic ETF ExpensesTypeHRTSNASDAQ ETFsAll ETFsManagement Fee0.99%0.54%0.53%Other Expenses0.00%0.52%0.56%Total Expense0.99%0.74%0.73%Fee Waiver-0.24%-0.50%-0.63%Net Expense0.75%0.63%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema GLP-1, Obesity & Cardiometabolic ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesWeight-Loss Drug ETFs Generate Skinnier Returns Than ExpectedJune 11, 2025 | finance.yahoo.comHRT may help to protect the heartOctober 22, 2024 | dailymail.co.uk📉 Volatility Surges Amid Political Turmoil—Here's How Traders Are RespondingAs we move through a summer marked by political unrest, legal battles, and global tensions, market volatility has returned with a vengeance. The combination of domestic protests, ongoing legal challenges to federal policies, and international conflicts has created a complex trading environment.June 21, 2025 | Darwin (Ad)Investing in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comOil Prices Spike Amid Middle East TensionsOctober 8, 2024 | theglobeandmail.comGuardian Capital LP Launches Two New ETFs on CBOE CanadaOctober 8, 2024 | theglobeandmail.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema GLP-1, Obesity & Cardiometabolic ETF's stock was trading at $28.87 on January 1st, 2025. Since then, HRTS shares have decreased by 3.1% and is now trading at $27.98. View the best growth stocks for 2025 here. Who are Tema GLP-1, Obesity & Cardiometabolic ETF's major shareholders? Top institutional investors of Tema GLP-1, Obesity & Cardiometabolic ETF include Sterling Investment Advisors Ltd. (9.40%) and Flow Traders U.S. LLC (2.97%). How do I buy shares of Tema GLP-1, Obesity & Cardiometabolic ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema GLP-1, Obesity & Cardiometabolic ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema GLP-1, Obesity & Cardiometabolic ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Fund Details IssuerTema Global Fund NameTema GLP-1, Obesity & Cardiometabolic ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset Class BenchmarkN/A Category Focus Development Level Region Number of Holdings93 Fund Statistics Assets Under Management$50.25 million Average Daily Volume$0.00 Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest400 shs Miscellaneous Outstanding Shares1,900,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 9.71%Novo Nordisk A/SHolding Weight: 4.92%Abbott Laboratories (NYSE:ABT)Holding Weight: 4.41%AstraZeneca PLCHolding Weight: 4.14%Roche (OTCMKTS:RHHBY)Holding Weight: 4.06%UnitedHealth Group (NYSE:UNH)Holding Weight: 3.61%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.39%US DOLLARSHolding Weight: 3.19%Boston Scientific (NYSE:BSX)Holding Weight: 3.17%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.11%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema GLP-1, Obesity & Cardiometabolic ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema GLP-1, Obesity & Cardiometabolic ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
